Hedgehog pathway inhibitors

Hedgehog pathway inhibitors may be used to treat basal cell carcinoma that has spread to other parts of the body.

The hedgehog pathway, for which sonic hedgehog (Shh) is the most prominent ligand, is highly conserved and is tightly associated with embryonic development in a number of species. This pathway is also tightly associated with development of several types

Systemic therapy (sonidegib and vismodegib are hedgehog pathway inhibitors [HhIs]); Reference: NCCN: Basal Cell Skin Cancer Evidence Blocks

Hedgehog pathway signaling inhibitor ENV-101 blocks signals that can lead to lung fibrosis and scarring and may lead to remodeling of early

H H. pylori eradication agents H2 antagonists Hedgehog pathway inhibitors Hematopoietic stem cell mobilizer Heparin antagonists Heparins HER2 inhibitors

Developing the next generation of hedgehog pathway inhibitors. The emerging tumor resistance while treating advanced BCCs, as well as the early failures of the drug in colon and ovarian cancers highlight the need to develop next generation hedgehog pathway inhibitors to target more downstream portions of the pathway.

The Hedgehog (Hh) proteins comprise a group of secreted proteins that regulate cell growth, differentiation and survival. Inappropriate activation of the Hh signaling pathway has been implicated in the development of a variety of cancers. Hedgehog pathway inhibitors are a relatively new class of therapeutic agents that act by targeting the proteins involved in the regulation of Hh pathway

In vitro studies have demonstrated the effectiveness of inhibitors of the Hedgehog pathway in inhibiting proliferation in those sarcomas in which the components of the pathway are overexpressed. These results were confirmed by in vivo studies, which additionally proved the influence of Shh pathway inhibitors on limiting the metastatic potential

A new small-molecule inhibitor of the Hedgehog signaling pathway acts independently of Smoothened (Smo). Rather than acting through Smo, which is a GPCR-like protein of the pathway, the compound